Loading…
PMS-VORICONAZOLE is a brand name for Voriconazole, supplied as a powder for solution. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE .............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 4 WARNINGS AND PRECAUTIONS…
Verbatim from this product's HC label. Tap a section to expand.
pms-VORICONAZOLE is contraindicated in patients with known hypersensitivity to voriconazole or its excipients. For a complete listing see DOSAGE FORMS, COMPOSITION AND PACKAGING section of the product monograph. There is no information regarding cross-sensitivity between voriconazole and other azole antifungal agents.
Caution should be used when prescribing voriconazole to patients with hypersensitivity to other azoles. pms-VORICONAZOLE is a substrate and inhibitor of cytochrome P450 isozymes CYP2C19, CYP2C9 and CYP3A4. Thus, coadministration of voriconazole is contraindicated with drugs that are highly dependent on these isozymes for clearance and for which elevated plasma concentrations are associated with serious and/or life threatening events.
In addition, coadministration of voriconazole is contraindicated with drugs that significantly decrease voriconazole plasma concentrations due to induction of these isozymes (see DRUG INTERACTIONS). Coadministration of voriconazole is contraindicated with drugs that are CYP450 substrates and for which elevated plasma levels may result in serious and/or life-threatening events.
These drugs are listed in Table 1. Coadministration of voriconazole is contraindicated with drugs that are CYP450 inducers where significantly reduced voriconazole plasma levels may be associated with the potential for serious and/or life-threatening events.
These drugs are listed in Table 1.
Table 1:
Drugs That Are Contraindicated with Voriconazole Drug class Drugs within class that are Contraindicated with pms-VORICONAZOLE Clinical comment Antiarrhythmic agents quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias Anticonvulsants carbamazepine, long acting barbiturates CONTRAINDICATED due to potential to significantly reduce plasma voriconazole concentrations Antihistamines astemizole*, terfenadine* CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias Antimycobacterial rifampin, rifabutin CONTRAINDICATED due to effect in significantly reducing plasma concentration of voriconazole Antipsychotic pimozide CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias Ergot derivatives ergotamine, dihydroergotamine CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as egotism Gastrointestinal (GI) Motility Agent cisapride* CONTRAINDICATED due to potential for serious and/or pms-VORICONAZOLE Product Monograph Page 5 of 53 life-threatening reactions such as cardiac arrhythmias Herbal Products St.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Voriconazole in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
John’s Wort** (Hypericum perforatum) CONTRAINDICATED due to its effect in significantly reducing plasma exposure of voriconazole Immunosuppressant sirolimus CONTRAINDICATED due to voriconazole’ s effect in significantly increasing plasma exposure of sirolimus Protease inhibitor ritonavir (high dose) CONTRAINDICATED due to its effect in significantly reducing plasma exposure of voriconazole Non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (doses of 400 mg once daily or higher) CONTRAINDICATED due to its effect in significantly reducing plasma exposure of voriconazole * Not marketed in Canada ** also P-gp inducer WARNINGS AND PRECAUTIONS Serious Warnings and Precautions Drug Interactions (see CONTRAINDICATIONS and DRUG INTERACTIONS)- pms-VORICONAZOLE significantly increases plasma concentrations of CYP450 substrates which may lead to serious or life threatening events - coadministration with CYP450 inducers significantly decreases plasma concentrations of voriconazole.
Cardiovascular effects - QT interval prolongation pms-VORICONAZOLE has been associated with prolongation of the QT interval of the electrocardiogram in some patients. Prolongation of QT interval may increase the risk of arrhythmia.
During the clinical development and post-marketing surveillance, there have been rare cases of arrhythmias (including ventricular arrhythmia such as torsades de pointes), cardiac arrests and sudden deaths in patients taking voriconazole.
These cases usually involved patients with risk factors and concomitant medications that may have been contributory. Caution should be exercised if voriconazole is used in patients taking other drugs that may prolong the QT interval (see WARNINGS AND PRECAUTIONS, Cardiovascular).
Visual disturbances: Voriconazole may cause visual symptoms including photophobia, altered/enhanced visual perception, blurred vision and/or color vision change (see WARNINGSAND PRECAUTIONS, Ophthalmologic). Hepatic toxicity: In clinical trials, there have been uncommon cases of serious hepatic reactions during treatment with pms-VORICONAZOLE (including clinical hepatitis, cholestasis, and fulminant hepatic failure, including fatalities).
Instances of hepatic reactions were noted to occur primarily in patients with serious underlying medical conditions. Hepatic reactions, including hepatitis and jaundice, have occurred among patients with no other identifiable risk factors.
Liver dysfunction has usually been reversible on discontinuation of therapy (see WARNINGS AND PRECAUTIONS, pms-VORICONAZOLE Product Monograph Page 6 of 53 Hepatic). Dermatological reactions: There have been cases of exfoliative cutaneous reactions, such as Stevens-Johnson Syndrome, toxic epidermal necrolysis and erythema multiforme that have been observed during treatment with voriconazole.
If a patient develops an exfoliative cutaneous reaction, voriconazole should be discontinued (see WARNINGS AND PRECAUTIONS, Skin). Teratogenic in the rat: Voriconazole can cause fetal harm when administered to a pregnant woman. If this drug is used in pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus (see WARNINGS AND PRECAUTIONS, Special Populations, Pregnant Women, and TOXICOLOGY).
Skeletal adverse events: Fluorosis and […]